Keros Therapeutics, Inc. (NASDAQ:KROS) Short Interest Update

Keros Therapeutics, Inc. (NASDAQ:KROS - Get Free Report) was the recipient of a significant decline in short interest in the month of September. As of September 30th, there was short interest totalling 3,020,000 shares, a decline of 13.7% from the September 15th total of 3,500,000 shares. Based on an average daily trading volume, of 346,000 shares, the days-to-cover ratio is currently 8.7 days.

Wall Street Analyst Weigh In

A number of research analysts recently weighed in on the stock. Scotiabank started coverage on shares of Keros Therapeutics in a research note on Wednesday. They issued a "sector outperform" rating and a $77.00 price objective for the company. HC Wainwright reiterated a "buy" rating and set a $100.00 price objective on shares of Keros Therapeutics in a research note on Tuesday, June 18th. Truist Financial restated a "buy" rating and issued a $100.00 target price on shares of Keros Therapeutics in a research note on Tuesday, June 18th. Bank of America reduced their target price on Keros Therapeutics from $81.00 to $76.00 and set a "buy" rating for the company in a report on Thursday, September 12th. Finally, Oppenheimer assumed coverage on shares of Keros Therapeutics in a research report on Tuesday, June 25th. They issued an "outperform" rating and a $102.00 price objective for the company. Ten analysts have rated the stock with a buy rating, According to MarketBeat.com, the company has an average rating of "Buy" and a consensus target price of $89.11.

Keros Therapeutics Trading Up 3.0 %

Shares of KROS traded up $1.79 during trading hours on Wednesday, reaching $62.18. 584,100 shares of the company's stock traded hands, compared to its average volume of 372,704. Keros Therapeutics has a 12 month low of $27.02 and a 12 month high of $73.00. The stock has a market cap of $2.24 billion, a PE ratio of -11.73 and a beta of 1.23. The firm's 50 day simple moving average is $52.45 and its 200-day simple moving average is $52.01.

Keros Therapeutics (NASDAQ:KROS - Get Free Report) last announced its earnings results on Wednesday, August 7th. The company reported ($1.25) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.23) by ($0.02). The company had revenue of $0.04 million for the quarter. Keros Therapeutics had a negative net margin of 62,012.55% and a negative return on equity of 44.73%. During the same period in the previous year, the firm posted ($1.27) EPS. As a group, analysts expect that Keros Therapeutics will post -4.88 earnings per share for the current fiscal year.

Insider Buying and Selling at Keros Therapeutics

In other news, Director Carl L. Gordon sold 250,000 shares of the stock in a transaction on Tuesday, August 13th. The stock was sold at an average price of $44.01, for a total transaction of $11,002,500.00. Following the completion of the transaction, the director now owns 119,522 shares in the company, valued at approximately $5,260,163.22. This represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Corporate insiders own 22.90% of the company's stock.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently added to or reduced their stakes in KROS. Redmile Group LLC purchased a new stake in Keros Therapeutics during the first quarter valued at about $36,576,000. Darwin Global Management Ltd. raised its holdings in shares of Keros Therapeutics by 35.4% during the 1st quarter. Darwin Global Management Ltd. now owns 1,435,950 shares of the company's stock valued at $95,060,000 after buying an additional 375,523 shares in the last quarter. Price T Rowe Associates Inc. MD lifted its position in Keros Therapeutics by 17.0% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 1,218,504 shares of the company's stock worth $80,666,000 after buying an additional 176,803 shares during the last quarter. Vanguard Group Inc. lifted its position in Keros Therapeutics by 7.9% in the 1st quarter. Vanguard Group Inc. now owns 1,545,758 shares of the company's stock worth $102,329,000 after buying an additional 113,563 shares during the last quarter. Finally, Nantahala Capital Management LLC boosted its stake in Keros Therapeutics by 28.8% in the second quarter. Nantahala Capital Management LLC now owns 378,807 shares of the company's stock worth $17,311,000 after buying an additional 84,810 shares in the last quarter. 71.56% of the stock is currently owned by hedge funds and other institutional investors.

About Keros Therapeutics

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.